Top Stories
The agreement will see the companies combine their resources to hunt for small-molecule drug candidates targeting oncology.
In conjunction with the move, nChroma Bio will undertake a restructuring, which news sources suggested will cut the biotech's workforce by around half.
Chief medical officer Eric Hughes will step down, to be replaced on an interim basis by David Gardiner, who heads innovative medicines and clinical development, until a permanent successor is found.
The agency will make a decision on sonesitatug vedotin in the second quarter of 2027.
Kesimpta is expected to generate $8 billion in peak sales, up from $6 billion previously, with estimates for both Scemblix and Leqvio raised from $4 billion to $5 billion.
Conference News
ATYR2810 substantially inhibits tumor growth and metastasis of osteosarcoma to the lungs, the main driver of poor outcomes, in preclinical studies. Anti-tumor benefits continued after treatment with A...
Late-breaking presentation highlights durable clinical activity, including 57% overall response rate at recommended Phase 2 dose in biomarker-positive patientsTime on REM-422 treatment reached up to t...
CELMoD programs advance across multiple myeloma and lymphoma, with Phase 3 readouts for ZENBEXUS™ (iberdomide) and mezigdomide, and Phase 2 data for golcadomideLandmark five-year TRANSFORM data demons...
Data Presented at the 2026 EORTC-NCI-AACR Symposium Show TROP2 Levels May Help Predict Which Tumors Respond to Reqorsa® and Modulating TROP2 May Enhance EfficacyAUSTIN, Texas, Nov. 19, 2026 /PRNewswir...
30% objective response rate and an 85% disease control rate on every 2-week (Q2W) schedule; all responses ongoing at data cut-offFavorable safety and tolerability profile with very few patients needin...



